Weight Loss

What to Look for in a Protein Powder?

Besides a balanced diet, many individuals opt to include supplements as part of their daily food intake. Protein powder is one such supplement which has become increasingly popular over recent years, with many users who want to achieve weight loss and muscle growth.

How Does Semaglutide Work to Lose Weight?

Weight Loss After Bariatric Surgery

Military Diet: Health Risks

Wegovy: A Breakthrough in Weight Loss?

Does Cinnamon Help with Weight Loss?

Is Cottage Cheese Good for Weight Loss? Evidence from Clinical Studies

Unexplained Weight Loss: When It Might Signal a Health Problem

Semaglutide and Weight Loss in Menopause

Who Should Take Weight Loss Injections, and Who Shouldn’t?

What Is Cancer Cachexia? Causes, Symptoms, Diagnosis, and Treatment

Is a Hypocaloric Diet Safe and Effective for Long-Term Health?

See more featured articles »

How Oral GLP-1 Drugs Work For Weight Loss

Circadian Rhythm and Weight Loss

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

Cachexia / Wasting Syndrome

Cachexia and Cancer

Vegetarian Diets for Weight Loss

The Natural Molecule That Could Rival Ozempic

Mental Health Disorders, Weight Gain, and Exercise

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Latest Weight Loss News and Research

Researchers identify a previously unknown mechanism that can drive cancer cachexia

Researchers at Helmholtz Munich, the Heidelberg Faculty of Medicine at Heidelberg University, the German Center for Diabetes Research (DZD) and the Technical University of Munich (TUM), have identified a previously unknown mechanism that can drive cancer cachexia – a wasting process in the body that primarily affects muscle and fat tissue.

1 Sep 2026

Study identifies three distinct BMI trajectories among people with type 2 diabetes

A recent study by the University of Eastern Finland identified three distinct body mass index (BMI) trajectories among people with type 2 diabetes.

1 Sep 2026

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

A narrative review suggests GLP-1-based therapies deliver metabolic, cardiovascular, renal, and other systemic benefits, raising interest in whether lower fractional doses could improve tolerability and treatment continuity. However, direct evidence for GLP-1 microdosing remains extremely limited, and researchers say prospective studies are needed to determine whether lower doses preserve long-term benefits.

1 Sep 2026

Semaglutide did more than cut weight in this analysis of 6,239 adults

A systematic review and meta-analysis of nine randomized controlled trials involving 6,239 adults with overweight or obesity without diabetes found that subcutaneous semaglutide produced substantially greater reductions in body weight, waist circumference, and C-reactive protein than placebo. The higher dose of 7.2 mg semaglutide showed potential for greater weight loss, although the evidence is largely based on a single trial and requires confirmation.

31 Aug 2026

New dual-drug strategy blocks triple-negative breast cancer growth

Triple-negative breast cancer (TNBC) has a frustrating ability to adapt. Although this aggressive form of breast cancer can initially respond well to chemotherapy, cancer cells often find ways to survive, allowing the disease to return and become resistant to treatment.

31 Aug 2026

The scale told a similar story across three diets. The liver told a different one

In a randomized controlled trial of people with metabolically unhealthy obesity, approximately 10% weight loss improved insulin sensitivity and several cardiometabolic measures across ketogenic, Mediterranean, and very-low-fat plant-forward diets. However, the very-low-carbohydrate ketogenic diet produced larger improvements in hepatic insulin sensitivity and greater reductions in liver fat and several glucose and insulin measures than the higher-carbohydrate diets.

31 Aug 2026

Experts call for safer weight loss as concerns grow over GLP-1 use

An editorial in Diabetology International argues that inappropriate GLP-1 use should be judged not only by regulatory compliance or off-label prescribing, but also by whether weight reduction is medically safe, nutritionally adequate, and properly supervised. Drawing on Japanese reports of ketosis and ketoacidosis following inappropriate tirzepatide use, the authors call for greater attention to the risks of unsafe weight-loss practices alongside medication-related harms.

30 Aug 2026

Is there a best day to take GLP-1 drugs? Researchers looked for an answer

A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing. The limited evidence suggests flexible dosing may support adherence and tolerability without compromising glycemic control or weight loss, but these findings rely largely on indirect evidence and expert opinion rather than direct comparative trials.

30 Aug 2026

Researchers identify early molecular warning signs of inflammatory bowel disease

Researchers have uncovered early molecular warning signs of inflammatory bowel disease, revealing the condition can begin before symptoms appear and continue silently even when patients appear well.

From Walter and Eliza Hall Institute of Medical Research (WEHI) 29 Aug 2026

Compound PF-04457845 slows motor decline in ALS mouse models

Amyotrophic lateral sclerosis (ALS) is a severe neurological disease that destroys nerve cells responsible for muscle movement.

28 Aug 2026

Personalized nutrition promotes weight loss without counting calories

The great majority of people taking part in a study lost weight by following personalised nutritional insights, rather than going on a calorie counting or restrictive diet, reveal findings from a new study.

27 Aug 2026

Ketogenic diet excels at reversing prediabetes and fatty liver

There is no shortage of popular diets to try, and they can generally produce weight loss if followed to the letter. But are all diet plans created equal in terms of reducing the cardiometabolic risks that come with obesity, such as Type 2 diabetes and liver disease?

27 Aug 2026

Ketogenic diet provides greatest health benefits for treating obesity

A diet that severely limits carbohydrates but is high in fat has the greatest health benefits for people with obesity compared to a Mediterranean diet or a low-fat diet, according to a clinical trial publishing August 27 in the Cell Press journal Cell Metabolism.

27 Aug 2026

Men see traditional dieting as restrictive and female-focused, study finds

A new study has identified why many men struggle with weight loss, finding that traditional diet programmes are often perceived as too restrictive and primarily aimed at women.

26 Aug 2026

GLP-1 drugs may reshape obesity care, but clinicians still have questions

Interviews with 11 healthcare professionals in a UK specialist weight management service found generally positive attitudes toward injectable GLP-1 drugs, alongside limited formal training and uncertainty about how the medications should be integrated with behavioral care. Participants anticipated potential benefits for confidence and weight management but also raised concerns about treatment discontinuation, behavioral engagement, and evolving professional responsibilities.

26 Aug 2026

A year after women lost weight, researchers saw which health gains lasted and which faded

Diet-induced weight loss significantly reduced predicted 10-year risks of major adverse cardiovascular events and type 2 diabetes in healthy premenopausal women with overweight, regardless of whether aerobic or resistance exercise was added. Some of these gains diminished as weight was partially regained over the following year, although greater exercise adherence was associated with less rebound in predicted diabetes risk.

25 Aug 2026

Consistent meal logging drives major weight loss in app users

The people who log their meals most days of the week lose the most weight. This is the central finding of a peer-reviewed study of 5132 MyNetDiary users, published on August 13, 2026, in the Journal of Medical Internet Research.

25 Aug 2026

Researchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetes

A large retrospective cohort study found that GLP-1 receptor agonist use was associated with a lower risk of tuberculosis in people with type 2 diabetes compared with sulfonylureas, metformin, DPP-4 inhibitors, and SGLT2 inhibitors. The observational findings suggest a possible benefit beyond metabolic control, but the authors emphasize that prospective and mechanistic studies are needed to determine whether GLP-1 therapies themselves reduce TB risk.

24 Aug 2026

Semaglutide’s heart benefits may partly involve reduced inflammation

A prespecified analysis of 17,604 SELECT participants found that higher baseline hsCRP was associated with greater risks of major cardiovascular events and death in people with overweight or obesity and established cardiovascular disease. Semaglutide produced rapid and sustained reductions in hsCRP, with changes emerging before substantial weight loss, although the study could not establish whether reduced inflammation directly mediated its cardiovascular benefits.

24 Aug 2026

A two-year diet trial challenges the idea that weight loss is the only result that matters

In the two-year DELISH randomized trial, adults with obesity achieved modest, sustained weight loss with either an adapted Mediterranean-style program or a commercial weight loss program. The Mediterranean-style intervention produced greater improvements in self-reported diet quality, while 24-month weight loss did not materially differ between groups.

24 Aug 2026